Duo of directors appointed at Dyax
This article was originally published in Scrip
Dyax Corp, a developer of novel biotherapeutics for unmet medical needs, has appointed Dr Ron Cohen and Paolo Pucci to its board of directors. In addition, Dr Cohen will serve on the compensation committee and Mr Pucci on the audit committee. Dr Cohen is the founder, president and CEO of Acorda Therapeutics, and Mr Pucci is CEO and a director of ArQule.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.